MS Pharma develops, manufactures, and distributes generic and biologic therapies across the MENA region. The company operates five manufacturing facilities in Jordan, Algeria, and Saudi Arabia, including a newly launched biologics plant that received SFDA GMP approval for biologics manufacturing. MS Pharma employs over 2,000 people across 12 countries and is headquartered in Amman, Jordan, with management offices in Zug, Switzerland. It aims to expand its biosimilars portfolio, deepen manufacturing capacity and supply-chain resilience, and become the first supplier of locally manufactured biologics to the Saudi market. The company plans to collaborate more with global development and licensing partners and to support exports into global markets.

Total raised

$45M

Funding rounds

2

Latest round

Equity

Latest activity

May 2017